Needham & Co Initiates Coverage on Celsion Corporation (CLSN) with a Buy
More News related to CLSN
- Data Monitoring Committee Recommends Continuation of Celsion's Phase III ThermoDox(R) Study for Primary Liver Cancer
- Celsion to Host Research and Development Day in New York City on February 24, 2010
- Celsion Abstract Selected for Oral Presentation at 2010 IHPBA World Congress in Buenos Aires, Argentina
- Medifocus, Inc. Announces Positive Clinical Results of Its Breast Cancer Treatment Studies Published in Annals of Surgical Oncology: Planning to Begin Phase III In Early 2010
- Celsion (CLSN) CFO Sean Moran Departs Company
More News related to New Coverage
- BMO Capital Initiates Coverage on Leap Wireless (LEAP) with a Market Perform
- Goldman Sachs Reinstates Citigroup (C) at Neutral
- FBR Research Initiates Coverage on MB Financial (MBFI) with a Market Perform; Taking Advantage of a Fragmented Deposit Market in Chicago
- Janney Montgomery Scott Initiates Coverage on Papa John's International (PZZA) with a Neutral
- Feltl & Co. Initiates Coverage on ActivIdentity (ACTI) with a Buy
Needham & Co initiates coverage on Celsion Corporation (Nasdaq: CLSN) with a Buy rating. Price target $7.
To see more analyst ratings on CLSN Click Here.
Celsion Corporation, an oncology drug development company, develops and commercializes targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology.
Related Categories
New CoverageStocks Mentioned
+0.00Related Entities
Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
Celsion
Mike on Nov 12, 2009 09:59 AMWhat is the rational of the upgrade. Their loss widens. No other news